Stockscreener 앱 받기
1.33
0.76%
0.01
시장 영업 전:
1.34
0.01
+0.75%
Telomir Pharmaceuticals Inc 주식(TELO)의 최신 뉴스
EXCLUSIVE: Telomir Pharmaceuticals Secures FDA Nod For Its Breast Cancer Therapy To Advance Into Human Study - Sahm
GLP safety trials find Telomir 1 well tolerated, Telomir Pharmaceuticals, Inc. asserts - Traders Union
Telomir Pharmaceuticals Receives FDA Clearance for IND of Telomir-Zn in Phase 1/2 Trial for Triple-Negative Breast Cancer 8 - Minichart
Telomir Says US FDA Clears Investigational New Drug Application for Telomir-Zn to Treat Triple-Negative Breast Cancer - marketscreener.com
Telomir Pharmaceuticals Receives FDA IND Clearance for Telomir-Zn - TipRanks
Telomir Pharmaceuticals (TELO) wins FDA IND clearance for Telomir‑Zn Phase 1/2 cancer trial - Stock Titan
Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer - Corsicana Daily Sun
FDA IND clearance puts Telomir's TNBC drug into first human testing - Stock Titan
Telomir shares surge after breakthrough tumor suppressor gene reactivation data - MSN
Telomir (TELO) CEO Aminov issued 7,319,710 shares in TELI acquisition - Stock Titan
Telomir Pharmaceuticals Acquires TELI, Secures Global Rights to Lead Drug Telomir-1 - citybuzz -
Telomir Pharmaceuticals completes TELI Pharmaceuticals acquisition By Investing.com - Investing.com India
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals and Files Form 8-K with Nasdaq Listing - Minichart
Telomir Pharmaceuticals Completes TELI Acquisition, Expands Telomir-1 Rights - TipRanks
Telomir completes acquisition of TELI Pharmaceuticals - Investing.com
Telomir Pharmaceuticals completes TELI Pharmaceuticals acquisition - Investing.com
Telomir completes acquisition of TELI Pharmaceuticals By Investing.com - Investing.com UK
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn) - ACCESS Newswire
Telomir Completes Acquisition of TELI Pharmaceuticals in All-Stock Deal, Issuing 34.4M Shares - TradingView
Telomir (NASDAQ: TELO) closes TELI acquisition, issues 34,389,710 shares and adds funding - Stock Titan
Telomir locks up worldwide rights to its lead drug, with $1M now and $4M tied to milestones - Stock Titan
TELO Telomir Pharmaceuticals gains slightly even as Q4 2025 EPS lands far below analyst consensus estimates. - UBND thành phố Hải Phòng
Telomir Pharmaceuticals unveils preclinical data for Telomir-1 at AACR Annual Meeting - Traders Union
Telomir Pharmaceuticals (TELO) Stock: Is It a Compelling Buy (Tumbles Hard) 2026-04-20Analyst Consensus - Xã Vĩnh Công
Telomir Pharmaceuticals (TELO) Stock: Why You Should Hold It (+2.29%) 2026-04-15Most Discussed Stocks - UBND thành phố Hải Phòng
Is Telomir Pharmaceuticals (TELO) Stock Lagging the Market | Price at $1.25, Up 2.46%Crowd Risk Alerts - Newser
Sentiment Review: Will Telomir Pharmaceuticals Inc outperform small cap indexesPortfolio Risk Summary & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Aug Wrap: How does Telomir Pharmaceuticals Inc compare to its peers2026 Intraday Action & Fast Moving Stock Trade Plans - baoquankhu1.vn
Is Telomir Pharmaceuticals (TELO) Stock Growing Now | Price at $1.30, Up 2.36%Chart Patterns - Newser
TELO SEC FilingsTelomir Pharms 10-K, 10-Q, 8-K Forms - Stock Titan
Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer - ACCESS Newswire
Is Telomir Pharmaceuticals (TELO) Stock defensive in downturns | Price at $1.27, Down 3.79%Stock Analysis - Newser
Telomir Pharmaceuticals submits IND in U.S. for Telomir-1 in TNBC - BioWorld News
Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) Targeting Advanced Triple-Negative Breast Cancer - Minichart
Telomir submits IND application for cancer drug candidate By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals Regains Nasdaq Listing Rule Compliance - TipRanks
Telomir Pharmaceuticals Regains Nasdaq Compliance Following 2025 Annual Shareholders Meeting - Minichart
Telomir Pharmaceuticals Submits IND for Telomir-1 in Advanced Triple-Negative Breast Cancer - National Today
Telomir Pharmaceuticals regains Nasdaq compliance after annual meeting - Investing.com
Nasdaq confirms Telomir (NASDAQ: TELO) back in listing compliance - Stock Titan
Telomir submits IND application for cancer drug candidate - Investing.com
Telomir takes experimental TNBC therapy to FDA for metastatic disease - Stock Titan
Telomir Pharmaceuticals submits IND application to FDA for Telomir-1 in TNBC By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals submits IND application to FDA for Telomir-1 in TNBC - Investing.com
Telomir submits IND for Telomir-1 to treat advanced and metastatic TNBC - TradingView
Telomir Pharmaceuticals (NASDAQ: TELO) files IND for Telomir-1 in advanced TNBC - Stock Titan
Telomir Shareholders Approve Equity Plan and Bylaw Changes - The Globe and Mail
Pullback Watch: Is Telomir Pharmaceuticals Inc stock a buy or sell2026 Weekly Recap & Technical Confirmation Trade Alerts - baoquankhu1.vn
Telomir Pharmaceuticals 2026 Annual Meeting Results: Shareholder Votes, Amended Bylaws, and Incentive Plan Approval - Minichart
Telomir Pharmaceuticals, Inc. unveils Telomir-1 for cellular dysfunction targeting iron and zinc balance - Traders Union
Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development - Bluffton Today
0.14%
0.48%
자본화:
|
볼륨(24시간):